7-107672245-G-T
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PS4PP1_ModeratePS3_SupportingPP4PP3PM3PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The p.Val138Phe variant in SLC26A4 has been detected in over 4 patients with Pendred syndrome or hearing loss with enlarged vestibular aqueducts who harbored a pathogenic or suspected pathogenic variant in trans with p.Val138Phe (PM3_VS; PMID:17503324, 15689455, 20597900, 18285825, 23965030, 24224479, 21551164, 23273637, 12788906, 16570074). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMID:25999548, 23336812, 26683941). The p.Val138Phe variant in SLC26A4 has been reported to segregate with hearing loss in at least 2 family members (PP1_M; PMID:12788906). The allele frequency of the p.Val138Phe variant in the SLC26A4 gene is 0.03% (38/126540) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). Computational prediction tools and conservation analysis suggest that the p.Val138Phe variant may impact the protein (PP3). At least one patient with a variant in this gene displayed features of EVA and/or Mondini malformation which are consistent with Pendred syndrome (PP4; PMID:12788906, 23273637). A functional study performed in HeLa and human embryonic kidney cell lines demonstrated that pendrin harboring the p.Val138Phe variant did not localize to the cell membrane. However, there was no effect on iodide efflux (PS3_P; PMID:11932316). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome/EVA based on the ACMG/AMP criteria applied: PM3_VS, PS4, PP1_M, PM2_Supporting, PP3, PP4, PS3_P. LINK:https://erepo.genome.network/evrepo/ui/classification/CA253312/MONDO:0010134/005
Frequency
Consequence
NM_000441.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC26A4 | NM_000441.2 | c.412G>T | p.Val138Phe | missense_variant | 4/21 | ENST00000644269.2 | NP_000432.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC26A4 | ENST00000644269.2 | c.412G>T | p.Val138Phe | missense_variant | 4/21 | NM_000441.2 | ENSP00000494017 | P1 | ||
SLC26A4 | ENST00000440056.1 | downstream_gene_variant | 4 | ENSP00000394760 |
Frequencies
GnomAD3 genomes AF: 0.000184 AC: 28AN: 151896Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000175 AC: 44AN: 251236Hom.: 0 AF XY: 0.000162 AC XY: 22AN XY: 135788
GnomAD4 exome AF: 0.000268 AC: 379AN: 1412074Hom.: 1 Cov.: 24 AF XY: 0.000257 AC XY: 181AN XY: 705508
GnomAD4 genome AF: 0.000184 AC: 28AN: 152014Hom.: 0 Cov.: 31 AF XY: 0.000121 AC XY: 9AN XY: 74322
ClinVar
Submissions by phenotype
Pendred syndrome Pathogenic:7
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | research | Otorhinolaryngology Lab - LIM32, University of Sao Paulo School of Medicine Clinics Hospital | - | in compound heterozygosis with the c.554G>C variant in a subject with bilateral non-syndromic sensorineural prelingual hearing loss (sporadic) - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2003 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 20, 2019 | NM_000441.1(SLC26A4):c.412G>T(V138F) is classified as pathogenic in the context of Pendred syndrome. Sources cited for classification include the following: PMID 19204907, 15355436, 11375792, 21551164, 15689455, 12788906, 23273637, 19017801, 9618167, 11932316, 9070918 and 9618166. Classification of NM_000441.1(SLC26A4):c.412G>T(V138F) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, reviewed by expert panel | curation | ClinGen Hearing Loss Variant Curation Expert Panel | Sep 19, 2018 | The p.Val138Phe variant in SLC26A4 has been detected in over 4 patients with Pendred syndrome or hearing loss with enlarged vestibular aqueducts who harbored a pathogenic or suspected pathogenic variant in trans with p.Val138Phe (PM3_VS; PMID: 17503324, 15689455, 20597900, 18285825, 23965030, 24224479, 21551164, 23273637, 12788906, 16570074). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMID: 25999548, 23336812, 26683941). The p.Val138Phe variant in SLC26A4 has been reported to segregate with hearing loss in at least 2 family members (PP1_M; PMID: 12788906). The allele frequency of the p.Val138Phe variant in the SLC26A4 gene is 0.03% (38/126540) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). Computational prediction tools and conservation analysis suggest that the p.Val138Phe variant may impact the protein (PP3). At least one patient with a variant in this gene displayed features of EVA and/or Mondini malformation which are consistent with Pendred syndrome (PP4; PMID: 12788906, 23273637). A functional study performed in HeLa and human embryonic kidney cell lines demonstrated that pendrin harboring the p.Val138Phe variant did not localize to the cell membrane. However, there was no effect on iodide efflux (PS3_P; PMID: 11932316). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome/EVA based on the ACMG/AMP criteria applied: PM3_VS, PS4, PP1_M, PM2_Supporting, PP3, PP4, PS3_P. - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostics Lab, Nemours Children's Health, Delaware | May 15, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 09, 2024 | Variant summary: SLC26A4 c.412G>T (p.Val138Phe) results in a non-conservative amino acid change located in the SLC26A/SulP transporter domain (IPR011547) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00018 in 251236 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in SLC26A4 causing Pendred Syndrome (0.00018 vs 0.0035), allowing no conclusion about variant significance. c.412G>T has been reported in the literature in multiple individuals affected with Pendred Syndrome (example: Mey_2019). These data indicate that the variant is very likely to be associated with disease. The following publication has been ascertained in the context of this evaluation (PMID: 31633822). ClinVar contains an entry for this variant (Variation ID: 4835). Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 29, 2020 | Published functional studies demonstrate a damaging effect due to aberrant protein processing, with retention of pendrin in the endoplasmic reticulum and absence of proper pendrin assembly at the cell membrane (Taylor et al., 2002); Common variant in Caucasian populations, accounting for approximately 12% of pathogenic alleles in published studies of Western European individuals (Tsukada et al., 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Classified as pathogenic by the ClinGen Hearing Loss Expert Panel (Oza et al., 2018; ClinVar SCV000840515.3; Landrum et al., 2016); This variant is associated with the following publications: (PMID: 9618166, 21551164, 17503324, 23336812, 19608655, 11932316, 26969326, 23273637, 12788906, 26744121, 29986705, 30473558, 30762457, 29320412, 29984802, 27771369, 18285825, 26683941, 25999548, 24224479, 16570074, 15689455, 23965030, 20597900, 31980526, 31589614) - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | This sequence change replaces valine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 138 of the SLC26A4 protein (p.Val138Phe). This variant is present in population databases (rs111033199, gnomAD 0.03%). This missense change has been observed in individuals with Pendred syndrome (PMID: 9618166, 11932316, 12788906, 21551164, 23273637, 24224479, 26969326). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4835). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC26A4 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects SLC26A4 function (PMID: 11932316). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 11, 2018 | - - |
Autosomal recessive nonsyndromic hearing loss 4 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 18, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Oct 21, 2021 | PM3_Very_Strong, PS4, PP1_Moderate, PM2_Supporting, PP3, PP4, PS3_Supporting - |
SLC26A4-related disorder Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 14, 2024 | The SLC26A4 c.412G>T variant is predicted to result in the amino acid substitution p.Val138Phe. This variant has been reported to be causative for Pendred syndrome (Van et al. 1998. PubMed ID: 9618166; Borck et al. 2003. PubMed ID: 12788906; de Moraes et al. 2013. PubMed ID: 23273637). Functional studies show this variant results in loss of proper localization of the SLC26A4 protein to the cell membrane (Taylor et al. 2002. PubMed ID: 11932316). This variant is reported in 0.029% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | Across a selection of the available literature, the SLC26A4 c.412G>T (p.Val138Phe) missense variant has been identified in a total of 23 patients with hearing loss or Pendred syndrome, including in four in a homozygous state, 14 in a compound heterozygous state and five in a heterozygous state in whom a second variant was not identified. The variant was also found in a heterozygous state in at least two unaffected family members (Van Hauwe et al. 1998; Coyle et al. 1998; Campbell et al. 2001; Gonzales-Trevino et al. 2001; Taylor et al. 2002; Borck et al. 2003; Pryor et al. 2005; Pera et al. 2008; Kandasamy et al. 2011; Landa et al. 2013). Segregation with disease is reported to have been shown in several families (Van Hauwe et al. 1998; Gonzales-Trevino et al. 2001). The variant was absent from 214 controls and is reported at a frequency of 0.00033 in the European (non-Finnish) population of the Exome Aggregation Consortium. The Val138 residue is conserved among several other related sulfate transporter genes from different species. Functional studies have shown that the p.Val138Phe variant protein is retained in the endoplasmic reticulum and fails to reach the cell membrane leading to loss of protein activity (Taylor et al. 2002). Based on the collective evidence, the p.Val138Phe variant is classified as pathogenic for SLC26A4-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Hearing impairment Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Department of Otolaryngology – Head & Neck Surgery, Cochlear Implant Center | Apr 12, 2021 | PS1_Strong, PM2_Supporting, PM5_Moderate, PP3_Supporting - |
Rare genetic deafness Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 16, 2020 | The p.Val138Phe variant in SLC26A4 has been reported in more than 20 individuals with clinical features of Pendred syndrome or DFNB4 hearing loss, at least 10 of whom were homozygous or compound heterozygous (Borck 2003 PMID: 12788906, Campbell 2001 PMID: 11317356, Coyle 1998 PMID: 9618167, de Moraes 2013 PMID: 23273637, Gonzalez Trevino 2001 PMID: 11375792, Kandasamy 2011 PMID: 21551164, Pourova 2010 PMID: 20597900, Pryor 2005 PMID: 15689455, Taylor 2002 PMID: 11932316, Van Hauwe 1998 PMID: 9618166, LMM data). It has been identified in 0.03% (38/126540) European chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; rs111033199); however, this low frequency is consistent with the carrier frequency in the general population. In vitro functional studies provide some evidence that the p.Val138Phe variant may impact protein function (Taylor 2002 PMID: 11932316). In summary, this variant meets criteria to be classified as pathogenic for Pendred syndrome or nonsyndromic hearing loss in an autosomal recessive manner. ACMG/AMP criteria applied: PM3_VeryStrong, PS4, PM2_Supporting, PS3_Supporting. - |
Pendred syndrome;C3538946:Autosomal recessive nonsyndromic hearing loss 4 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 04, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at